Literature DB >> 25907284

B cells generated by B-1 development can progress to chronic lymphocytic leukemia.

Kyoko Hayakawa1, Anthony M Formica1, Matthew J Colombo1, Daiju Ichikawa1,2, Susan A Shinton1, Joni Brill-Dashoff1, Richard R Hardy1.   

Abstract

B cells generated early during fetal/neonatal B-1 development in mice include autoreactive cells with detectable CD5 upregulation induced by B cell receptor (BCR) signaling (B1a cells). A fraction of B1a cells are maintained by self-renewal for life, with the potential risk of dysregulated growth and progression to chronic lymphocytic leukemia (CLL)/lymphoma during aging. In studies using the Eμ-hTCL1 transgenic mouse system, it became clear that this B1a subset has a higher potential than other B cell subsets for progression to CLL. We have generated several autoreactive germline BCR gene models to compare B cells generated under conditions of natural exposure to autoantigen. Analysis of the mice has been key in understanding the importance of the BCR and BCR signaling for generating different B cell subsets and for investigating the cellular origin of B-CLL.
© 2015 New York Academy of Sciences.

Entities:  

Keywords:  B cell subsets; B-1 development; B-CLL; B1a; autoreactive BCR

Mesh:

Substances:

Year:  2015        PMID: 25907284     DOI: 10.1111/nyas.12768

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells.

Authors:  B Yigit; N Wang; S-S Chen; N Chiorazzi; C Terhorst
Journal:  Leukemia       Date:  2017-07-28       Impact factor: 11.528

2.  CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.

Authors:  Soizic Garaud; Taher E Taher; Marjolaine Debant; Miguel Burgos; Sarra Melayah; Christian Berthou; Kaushal Parikh; Jacques-Olivier Pers; Damien Luque-Paz; Gilles Chiocchia; Maikel Peppelenbosch; David A Isenberg; Pierre Youinou; Olivier Mignen; Yves Renaudineau; Rizgar A Mageed
Journal:  Cell Mol Immunol       Date:  2016-08-08       Impact factor: 11.530

Review 3.  Perspectives on fetal derived CD5+ B1 B cells.

Authors:  Richard R Hardy; Kyoko Hayakawa
Journal:  Eur J Immunol       Date:  2015-09-23       Impact factor: 5.532

4.  Ikaros Is a Negative Regulator of B1 Cell Development and Function.

Authors:  Alejandra Macias-Garcia; Beate Heizmann; MacLean Sellars; Patricia Marchal; Hayet Dali; Jean-Louis Pasquali; Sylviane Muller; Philippe Kastner; Susan Chan
Journal:  J Biol Chem       Date:  2016-02-03       Impact factor: 5.157

5.  Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Authors:  Sara S Alhakeem; Mary K McKenna; Karine Z Oben; Sunil K Noothi; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Vivek M Rangnekar; Natarajan Muthusamy; Subbarao Bondada
Journal:  J Immunol       Date:  2018-04-30       Impact factor: 5.422

6.  Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils.

Authors:  Paulina Wlasiuk; Artur Niedzielski; Katarzyna Skorka; Agnieszka Karczmarczyk; Joanna Zaleska; Malgorzata Zajac; Maciej Putowski; Elzbieta Pac-Kozuchowska; Krzysztof Giannopoulos
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

7.  Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.

Authors:  Aleena A Gladkikh; Daria M Potashnikova; Victor Tatarskiy; Margarita Yastrebova; Alvina Khamidullina; Natasha Barteneva; Ivan Vorobjev
Journal:  Cancer Med       Date:  2017-11-10       Impact factor: 4.452

8.  Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.

Authors:  Alejandro M Hortal; Clara L Oeste; Claudia Cifuentes; Miguel Alcoceba; Isabel Fernández-Pisonero; Laura Clavaín; Rut Tercero; Pilar Mendoza; Verónica Domínguez; Marta García-Flores; Belén Pintado; David Abia; Carmen García-Macías; Almudena Navarro-Bailón; Xosé R Bustelo; Marcos González; Balbino Alarcón
Journal:  Mol Cancer       Date:  2022-02-04       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.